Dr. Christopher C. Croot, MD
Hematology & Oncology (Hematology & Oncology Physician)
911 Bypass Rd Bldg A
Pikeville, KY 41501
Who else practices at this address →
Pike County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Kentucky College of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 175
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Kentucky College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 48124 · MS license 14930
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Pikeville Medical Center Pikeville, KY
Medical groups
- Pikeville Medical Center Inc (425 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 175
- Services billed
- 705
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 345 | 158 |
| Established patient office or other outpatient visit, 30-39 minutes | 49 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Pikeville, KY | 83 |
| Eliquis (apixaban) Other prescribers in Pikeville, KY | 80 |
| Prochlorperazine Maleate Other prescribers in Pikeville, KY | 60 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Pikeville, KY | 58 |
| Anastrozole Other prescribers in Pikeville, KY | 48 |
| Ondansetron Hcl Other prescribers in Pikeville, KY | 47 |
| Abiraterone Acetate | 44 |
| Levothyroxine Sodium Other prescribers in Pikeville, KY | 40 |
| Xtandi (enzalutamide) | 39 |
| Imatinib Mesylate | 33 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 152 payments worth $3,141 in total to this clinician.
| Food and Beverage | $3,121 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Mar 6, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $9,545 in research payments for these studies, mostly to the institutions running them.
- Fixed dose IV combination of atezo tira
Hoffmann-la Roche Limited - An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chem…
Ipsen Bioscience Inc. · NCT04083242 - A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT06644768 - A phase 1 dose escalation and cohort expansion study of TSR-022, an an
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.